B-cell leukemia protein-2 and peptide YY chemotherapy resistance in colon cancer.
BACKGROUND
Inhibition of apoptosis may allow cells with drug-induced damage to escape programmed cell death. The bcl-2 protein inhibits apoptosis and bcl-2 overexpression has been associated with drug resistance. It is our hypothesis that higher levels of bcl-2 expression will be seen in colon cancer cells resistant to PYY treatment.


METHODS
Caco2 and HCT116 colon cancer cells were treated with 2 microM PYY for 24 hours. Protein was extracted from cells surviving PYY treatment; bcl-2 expression was measured by enzyme-linked immunosorbent assay (ELISA) and confirmed by Western blotting.


RESULTS
Caco2 and HCT116 cells surviving PYY treatment demonstrated increased bcl-2 from 20.54+/-2.7 to 28.63+/-2.20 units/mL (P <0.05) and 21.98+/-1.28 to 29.32*+/-2.26 units/mL, respectively.


CONCLUSIONS
Increased expression of bcl-2 is seen in a population of colon cancer cells resistant to PYY. Hence, bcl-2 may protect neoplastic cells from apoptosis; its levels may be useful in predicting chemotherapy response and in selecting appropriate drug regimens.
Kling
K
K
Department of Surgery, University of California, Los Angeles, USA.
Kim
F
F
Cole
M
M
McFadden
D
D
D017209:Apoptosis; D015153:Blotting, Western; D002470:Cell Survival; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D019254:Genes, bcl-2 / Q000235:genetics*; D006801:Humans; D019894:Peptide YY / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis* / Q000235:genetics; D014407:Tumor Cells, Cultured
D019253:Proto-Oncogene Proteins c-bcl-2; D019894:Peptide YY